Motoyasu Satou
University of Alberta
Heterologous expressionPhysicsNull cellBiophysicsInternal medicineDownregulation and upregulationOncologyGene expressionEndogenyDomain (software engineering)STAT proteinGene knockdownChemistryApoptosisStructural biologySensitivity (control systems)Electronic engineeringDisinhibitionTemozolomideCarcinomaCapecitabineSTAT3Amino acid transporterPituitary tumorsLeucine transportResponse controlVoltage sensingSecretionIon channelCancer researchRadiation therapyClinical trialCarcinogenesisCell growthHormoneMedicineCorticotropic cellPotassium channelTranscription factorPI3K/AKT/mTOR pathwayCancer cell
5Publications
2H-index
6Citations
Publications 5
Newest
#1Tae Nakano-Tateno (U of A: University of Alberta)H-Index: 3
#2Motoyasu Satou (U of A: University of Alberta)H-Index: 2
Last. Constance L. Chik (U of A: University of Alberta)H-Index: 29
view all 8 authors...
Corticotroph carcinomas and aggressive corticotroph tumors can be resistant to conventional therapy, including surgery, radiotherapy, and medical treatment. Recent evidence suggests that temozolomide (an oral alkylating agent) administered with capecitabine (pro-drug of 5-fluorouracil) may improve progression-free survival in patients with high-risk corticotroph tumors and carcinomas. This led to the use of capecitabine and temozolomide (CAPTEM) in two patients, one with a corticotroph carcinoma...
2 CitationsSource
#1Cyndy Liu (U of A: University of Alberta)
#2Tae Nakano-Tateno (U of A: University of Alberta)H-Index: 3
Last. Toru Tateno (U of A: University of Alberta)H-Index: 14
view all 5 authors...
Pituitary adenomas are benign tumours that can cause an individual various clinical manifestations including tumour mass effects and/or the diverse effects of abnormal pituitary hormone secretion. Given the morbidity and limited treatment options for pituitary adenomas, there is a need for better biomarkers and treatment options. One molecule that is of specific interest is the signal transducer and activator of transcription 3 (STAT3), a transcription factor that plays a critical role in mediat...
Source
#1Shawn M. Lamothe (U of A: University of Alberta)H-Index: 7
#2Nazlee Sharmin (U of A: University of Alberta)H-Index: 3
Last. Harley T. Kurata (U of A: University of Alberta)H-Index: 22
view all 8 authors...
Many voltage-dependent ion channels are regulated by accessory proteins. We recently reported powerful regulation of Kv1.2 potassium channels by the amino acid transporter Slc7a5. In this study, we report that Kv1.1 channels are also regulated by Slc7a5, albeit with different functional outcomes. In heterologous expression systems, Kv1.1 exhibits prominent current enhancement ('disinhibition') with holding potentials more negative than -120 mV. Knockdown of endogenous Slc7a5 leads to larger Kv1....
1 CitationsSource
#1Motoyasu Satou (U of A: University of Alberta)H-Index: 2
#2Jason Wang (U of A: University of Alberta)H-Index: 1
Last. Toru Tateno (U of A: University of Alberta)H-Index: 14
view all 12 authors...
Abstract Pituitary tumors (PTs) can cause significant mortality and morbidity due to limited therapeutic options. L-type amino acid transporters (LATs), in particular, the LAT1 isoform, is expressed in a variety of tumor cells. Pharmacological inhibition or genetic ablation of LAT1 can suppress leucine transport into cancer cells, resulting in suppression of cancer cell growth. However, roles of LAT1 in PTs have not been elucidated. Therefore, we assessed LAT1 expression in PTs and evaluated a L...
4 CitationsSource
#1Shawn M. Lamothe (U of A: University of Alberta)H-Index: 7
#2Nazlee Sharmin (U of A: University of Alberta)H-Index: 3
Last. Harley T. Kurata (U of A: University of Alberta)H-Index: 22
view all 8 authors...
Source